Atezolizumab Drug Aliquot | Anti-PD-L1 | Therapeutic Antibody

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Atezolizumab are now available as research consumables.

Atezolizumab drug aliquots can be used for in vitro or in vivo experiments. For biosimilar development, different batches of Atezolizumab drug can be ordered at the same time. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Atezolizumab Reference Drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Tecentriq® / Atezolizumab Reference Product

Drug nameTecentriq®
INNAtezolizumab
API typehumanized IgG1
Pharmacotherapeutic group
Antineoplastic agents, monoclonal antibodies
ATC code
L01XC32
Target of antibody
PD-L1; Synonyms: CD274, B7-H, B7H1, PD-L1, PDCD1L1, PDCD1LG1, PDL1, A530045L16Rik, B7h1, Pdcd1l1,
Pdcd1lg1, Pdl1, RGD1566211
General functionAtezolizumab works by attaching to a specific protein in your body called programmed death-ligand 1 (PD-L1). This protein suppresses the body’s immune (defense) system, thereby protecting cancer cells from being attacked by the immune cells. By attaching to the protein, Atezolizumab helps your immune system to fight your cancer.
Short descriptionAtezolizumab is an Fc-engineered, humanised IgG1 anti-programmed death-ligand 1 (PD-L1) monoclonal antibody produced in Chinese hamster ovary cells by recombinant DNA technology

Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Programmed death-ligand 1 (PD-L1) may be expressed on tumour cells and/or tumour-infiltrating immune cells, and can contribute to the inhibition of the antitumour immune response in the tumour
microenvironment. Binding of PD-L1 to the PD-1 and B7.1 receptors found on T-cells and antigen-presenting cells suppresses cytotoxic T-cell activity, T-cell proliferation and cytokine production.
Atezolizumab is an Fc-engineered, humanised immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumour immune response without inducing antibody-dependent cellular cytotoxicity. Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)Atezolizumab is a Antineoplastic agent, with an Fc-engineered, humanized immunoglobulin G1 (IgG1) monoclonal antibody that directly binds to PD-L1 and provides a dual blockade of the PD-1 and B7.1 receptors, releasing
PD-L1/PD-1 mediated inhibition of the immune response, including reactivating the antitumor immune response without inducing antibody-dependent cellular cytotoxicity.
Atezolizumab spares the PD-L2/PD-1 interaction allowing PD-L2/PD-1 mediated inhibitory signals to persist
Original license holder
Roche Registration GmbH
Marketing authorisation numbers
EU/1/17/1220/002
Marketing authorisation holder
Roche Registration GmbH
Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany
(Date of first authorisation: 21 September 2017)
Name of the manufacturer of the biological active substance
F. Hoffmann-La Roche AG
Grenzacherstrasse 124
4070 Basel
SWITZERLAND
Name and address of the manufacturer(s) responsible for batch releaseRoche Pharma AG
Emil-Barell-Strasse 1
79639 Grenzach-Whylen
GERMANY
Max shelf life
36 months
Storage conditions
2°C – 8°C
List of excipients
L-histidine
Glacial acetic acid
Sucrose
Polysorbate 20

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.